ANDROGENS, ESTROGENS AND PROGESTERONE IN PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA, RELATION WITH GROWTH AND TRANCRIPTION FACTORS

Authors: Kovaleva I.V¹, Spirina L.V¹^,2
Affiliations:
1. Siberian State Medical University
2. Cancer Research Institute, Tomsk NMRC of the RAS
Issue: Vol 15, No 3S (2020)
Pages: 94-95
Section: Articles
URL: https://genescells.ru/2313-1829/article/view/122829
DOI: https://doi.org/10.23868/gc122829
ID: 122829

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Siberian State Medical University

Siberian State Medical University; Cancer Research Institute, Tomsk NMRC of the RAS

Tomsk, Russia

Schatten H. Brief Overview of Prostate Cancer Statistics, Grading, Diagnosis and Treatment Strategies. Adv Exp Med Biol. 2018; 1095:1-14.
Feng Q., He B. Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer. Front Oncol. 2019; 9: 858.
Chen R., Yu Y., Dong X. Progesterone receptor in the prostate: A potential suppressor for benign prostate hyperplasia and prostate cancer. J Steroid Biochem Mol Biol. 2017; 166: 91-96. А.А. Коваленко, М.В. Захарова, А.П. Шварц,

Supplementary Files

Action

1. JATS XML